Manganese-enhanced MRI: Comparison of agents in the rat pancreas
Mangafodipir was approved for use as an MRI contrast agent in the late 1990s for liver and pancreas imaging but it was removed from the European market for commercial reasons in 2012. Previously, preliminary work in mice and in diabetic patients showed that Mn2+ ions could be used as a contrast agen...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-12-01
|
Series: | Journal of Magnetic Resonance Open |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666441020300029 |